Summary
The pharmacokinetics of estramustine phosphate (EMP) was studied in five prostatic cancer patients given single i.v. and oral doses of EMP in a cross-over study. Plasma and urinary concentrations of parent drug, estramustine, estromustine (the estrone analogue), estradiol and estrone were followed for 32 h. The elimination of intravenous EMP from plasma was biphasic. The mean volumes of distribution were small, being 43 and 108 ml/kg for the central and peripheral compartments, respectively. The plasma clearance was 64 ml/kg/h, and the half-lives of the two phases were 0.16 and 1.27 h. Metabolism was the major route of elimination of EMP. It was readily dephosphorylated and oxidized to yield the cytotoxic metabolites estramustine and estromustine. Estromustine was the main metabolite in plasma. When given orally EMP underwent extensive presystemic dephosphorylation, which started in the gastrointestinal tract. The relative bioavailability of estromustine after administration of EMP-capsules was 44%, which reflects incomplete absorption of EMP rather than first-pass metabolism of estromustine. The terminal half-life of estromustine was 10–20 h, which suggests that EMP might be given once or twice a day.
Similar content being viewed by others
References
Jönsson G, Högberg B (1971) Treatment of advanced prostatic carcinoma with Estracyt. Scand J Urol Nephrol 5: 103–107
Mittelman A, Shukla SK, Murphy GP (1976) Extended therapy of stage D carcinoma of the prostate with oral Estracyt. J Urol 115: 409–412
Jönsson G, Högberg B, Nilsson T (1977) Treatment of advanced prostatic carcinoma with estramustine phosphate (Estracyt®). Scand J Urol Nephrol 11: 231–238
Andersson L, Edsmyr F, Jönsson G, Könyves I (1977) Estramustine phosphate therapy in carcinoma of the prostate. Recent Results Cancer Res 60: 73–77
Nagel R, Kölln C-P (1977) Treatment of advanced carcinoma of the prostate with Estracyt. Br J Urol 49: 73–79
Andersson S-B, Lundgren R, Svensson L (1982) Gas chromatographic determination of four metabolites of estramustine phosphate in plasma. Acta Pharm Suec 19: 1–10
Brooks MA, Dixon R (1980) Determination of estramustine and its 17-keto metabolite in plasma by high performance liquid chromatography. J Chromatogr 182: 387–394
Andersson S-B, Gunnarsson PO, Nilsson T, Plym Forshell G (1981) Metabolism of estramustine phosphate (Estracyt®) in patients with prostatic carcinoma. Eur J Drug Metab Pharmacokinet 6: 149–154
Dixon R, Brooks M, Gill G (1980) Estramustine phosphate: Plasma concentrations of its metabolites following oral administration to man, rat and dog. Res Commun Chem Pathol Pharmacol 27: 17–29
Forsgren B, Gunnarsson PO, Johansson S-Å, Kant R (1978) Radioimmunoassay of estramustine phosphate in plasma. Acta Pharm Suec 15: 200–210
Gunnarsson PO, Andersson S-B, Johansson S-Å (1984) In vitro studies on the metabolism of estramustine phosphate (Estracyt®). Eur J Drug Metab Pharmacokinet (in press)
Rowland M, Tucker G (1980) Symbols in pharmacokinetics. J Pharmacokinet Biopharm 8: 497–507
Rowland M, Tozer TN (1980) Clinical pharmacokinetics: Concepts and application. Lea & Febiger, Philadelphia, pp 1–331
Metzler CM, Elfring GL, McEwen AJ (1974) A package of computer programs for pharmacokinetic modeling. Biometrics 30: 562–572
Gunnarsson PO, Plym Forshell G, Fritjofsson Å, Norlén BJ (1981) Plasma concentrations of estramustine phosphate and its major metabolites in patients with prostatic carcinoma treated with different doses of estramustine phosphate (Estracyt®). Scand J Urol Nephrol 15: 201–206
Heel RG, Avery GS (1980) Drug data information. In: Avery GS (ed) Drug treatment, principles and practice of clinical pharmacology and therapeutics. 2nd ed. Adis Press, Sydney New York, pp 1211–1222
Plym Forshell G, Müntzing J, Ek A, Lindstedt E, Dencker H (1976) The absorption, metabolism and excretion of Estracyt in patients with prostatic cancer. Invest Urol 14: 128–131
Kirdani RY, Mittelman A, Murphy GP, Sandberg AA (1975) Studies on phenolic steroids in human subjects. XIV. Fate of a nitrogen mustard of estradiol-17β. J Clin Endocrinol Metab 41: 305–318
Balant LP, McAinsh J (1980) Use of metabolite data in the evaluation of pharmacokinetics and drug action. In: Jenner P, Testa B (eds) Concepts in drug metabolism, Part A, Vol. 10. Marcel Dekker, New York Basel, pp 311–371
Björk P, Forsgren B, Gustafsson J-Å, Pousette Å, Högberg B (1982) Partial characterization and “quantitation” of a human prostatic estramustine-binding protein. Cancer Res 42: 1935–1942
Leistenschneider W, Nagel R (1980) Estracyt therapy of advanced prostatic cancer with special reference to control of therapy with cytology and DNA cytophotometry. Eur Urol 6: 111–115
Hartley-Asp B, Gunnarsson PO (1982) Growth and cell survival following treatment with estramustine, nor-nitrogen mustard, estradiol and testosterone of a human prostatic cancer cell line (DU 145). J Urol 127: 818–822
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gunnarsson, P.O., Andersson, S.B., Johansson, S.Å. et al. Pharmacokinetics of estramustine phosphate (Estracyt®) in prostatic cancer patients. Eur J Clin Pharmacol 26, 113–119 (1984). https://doi.org/10.1007/BF00546718
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00546718